Fundraising FoxBiophytis
Paris · 6 known investors
Find your way into Biophytis
Sign up to see every warm intro you have to Biophytis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Biophytis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Biophytis is a clinical-stage biotechnology company developing drug candidates for age-related diseases and metabolic conditions, with a phase 2 trial in obesity. The company is publicly listed and raises capital from institutional investors to fund its clinical programs.
Founders & leadership
SV
Stanislas VeilletCo-founder
JM
Jean MarianiCo-founder
EB
Edouard BiethExecutive
WD
Waly DiohExecutive
Board
NC
Nadine CoulmBoard director
CA
Claude AllaryBoard director
Investors · 6
Also in the syndicate · 4
Alumni CapitalAlumni Capital Management LLCBigger CapitalHexagon Capital Fund
Reported raises · per SEC filings
Form D private placements$4.2M disclosed across 2 of 3 rounds · 2025–2026
▶$2.6MraisedSep 2026 · 3 investors · BiotechnologyRule 506(b)
▶$2.6MraisedSep 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stanislas VeilletExecutive Officer, Director
- Claude AllaryDirector
- Nadine CoulmDirector
- Jean MarianiExecutive Officer, Director
- Christophe CourtillatExecutive Officer
- Edouard BiethExecutive Officer
- Chiara BaccelliExecutive Officer
- Pierre DildaExecutive Officer
- Waly DiohExecutive Officer
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- Sales commissions
- $181.9K
- Placement agents
- Maxim Group, LLC
- First sale
- Sep 2026
- Incorporated
- Corporation, France
- Federal exemptions
- 06b
▶$1.6MraisedMar 2026 · 3 investors · BiotechnologyRule 506(b)
▶$1.6MraisedMar 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stanislas VeilletExecutive Officer, Director
- Edouard BiethExecutive Officer
- Jean MarianiExecutive Officer, Director
- Waly DiohExecutive Officer
- Chiara BaccelliExecutive Officer
- Nadine CoulmDirector
- Pierre DildaExecutive Officer
- Christophe CourtillatExecutive Officer
- Claude AllaryDirector
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- Sales commissions
- $111.8K
- Placement agents
- Maxim Group, LLC
- First sale
- Mar 2026
- Incorporated
- Corporation, France
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Biophytis do?
- Biophytis is a clinical-stage biotechnology company developing drug candidates for age-related diseases and metabolic conditions, with a phase 2 trial in obesity. The company is publicly listed and raises capital from institutional investors to fund its clinical programs.
- Who founded Biophytis?
- Biophytis was founded by Stanislas Veillet, Jean Mariani.
- Who are Biophytis's investors?
- Biophytis's investors include Agoranov, Kreos Capital.
- How much funding has Biophytis raised?
- Biophytis has disclosed $4.2M raised across 2 of its 3 known rounds.
- Where is Biophytis headquartered?
- Biophytis is headquartered in Paris.